USPTO serial 79306175
VOZRIA
Reviewed by CopyMark Law Group
- Filing date
- Status date
- Registration date
- Nov 9, 2021
- Examiner
- CIANCI, RYAN MICHAEL
- Law office
- PUBLICATION AND ISSUE SECTION
What this means
This registration is in, or will soon enter, a USPTO maintenance window. Missing a Section 8 or Section 9 filing can cancel the registration.
Need help with VOZRIA?
If you own this trademark, we can monitor new filings and help with USPTO deadlines. If you do not, we can file a new U.S. application.
Current trademark owner
Get help with this Renewal, set up monitoring, or talk with CopyMark.
Get Attorney Assistance for just $299*
Plus Government fees of $325
Not the owner?
File a new U.S. trademark application, or speak with our attorneys.
Owner
Goods and services
| Class | Description | Status | First use |
|---|---|---|---|
| 005 | Pharmaceutical preparations for use as anti-infectives; pharmaceutical preparations for the treatment of viral conditions, namely, human immunodeficiency virus (hiv), human papilloma virus, respiratory syncytial virus, hepatitis, herpes genitalis, herpes labialis, herpes simplex virus, varicella-zoster virus, epstein-barr virus and cytomegalovirus; pharmaceutical preparations for the treatment and prevention of respiratory diseases and disorders and their symptoms; pharmaceutical preparations for the treatment of immune system related diseases and disorders, namely, immunosuppressants; pharmaceutical preparations for the treatment of immunologic diseases and disorders, namely, autoimmune diseases and disorders; pharmaceutical preparations for the treatment of atherosclerosis; pharmaceutical preparations for the treatment of viral conditions, namely, human immunodeficiency virus (hiv), hpv, rsv, hepatitis, herpes genitalis, herpes labialis, herpes simplex virus, varicella-zoster virus, epstein-barr virus and cytomegalovirus; pharmaceutical preparations for the treatment and prevention of metabolic related diseases and disorders, namely, disorders of the endocrine system, namely, growth and thyroid disorders, diabetes, metabolic syndrome, obesity, weight loss and weight management; pharmaceutical preparations for the treatment and prevention of cardiovascular, cardiopulmonary, cardio-renal and renal diseases and disorders; pharmaceutical preparations for the prevention and treatment of oncological diseases and disorders; pharmaceutical preparations for the treatment of inflammation and inflammatory related diseases and disorders, namely, arthritis, rheumatoid arthritis, inflammatory bowel diseases, inflammatory connective tissue diseases, vasculitis, synovitis; pharmaceutical preparations for the prevention and treatment of sequelae of oncologic diseases and their treatment, namely, nausea and vomiting, hematologic depression, mucositis, cachexia, pain, bone pain and fatigue; pharmaceutical preparations for the treatment of blood-related diseases and disorders, namely, thrombocytopenia, coagulation disorders, bleeding disorders, platelet disorders, blood vessel disorders, sickle-cell disease and its related disorders, anemias, sepsis and infections in and of the blood; pharmaceutical preparations for the treatment of musculoskeletal diseases, disorders and injuries, namely, connective tissue diseases, bone diseases, osteoporosis, spinal diseases, back pain, gout, fractures, sprains, sports injuries, osteogenesis imperfecta, muscle wasting (cachexia), renal osteodystrophy, cartilage injuries, joint replacement and osteoarthritis; pharmaceutical preparations for use in ophthalmology; pharmaceutical preparations for the treatment of dermatological diseases and disorders, namely, dermatitis, skin and skin structure infections, namely, bacterial skin infections, fungal skin infections, viral skin infections and parasitic skin infections, psoriasis, eczema and sexually transmitted diseases; pharmaceutical preparations for the treatment of hormonal related diseases and disorders, namely, hypogonadism, testosterone/androgen disorders and estrogen disorders; pharmaceutical preparations for the treatment of gastrointestinal related diseases and disorders, namely, irritable bowel disorders and symptoms, digestive disorders and acid-related disorders; pharmaceutical preparations for the treatment of sexual dysfunction, namely, erectile dysfunction, male and female sexual dysfunction disorders, namely, arousal disorder, pain disorder, desire disorder and orgasm disorder; pharmaceutical preparations for the treatment of genitourinary diseases, namely, urological diseases and disorders; pharmaceutical preparations for the treatment of gynaecological diseases and disorders, namely, amenorrhoea, dysmenorrheal and infertility; pharmaceutical hormonal preparations, namely, corticosteroids, hormone replacement therapy preparations, oral contraceptives, thyroid hormone preparations; pharmaceutical preparations for the treatment of incontinence, prostate diseases and disorders, bladder diseases and disorders; pharmaceutical preparations for the treatment of sexually transmitted diseases, inflammatory pelvic diseases, vasomotor/menopausal symptoms, endometriosis/uterine fibroids, leiomyoma, endourology/stone, pre-eclampsia and pre-term labour; pharmaceutical preparations for the treatment of prostatitis, nephritis, cystitis, vaginitis, renal disease; pharmaceutical preparations for the treatment of premenstrual dysphoric disorder, premenstrual syndrome, male hypogonadism and hormonal disorders, namely, polycystic ovary syndrome; pharmaceutical preparations for the treatment of hepatological related diseases, namely, hepatitis, non-alcoholic fatty liver disease (nafld), non-alcoholic steatohepatitis (nash), liver fibroids, and cirrhosis; pharmaceutical preparations for the treatment of alopecia and androgenic alopecia (male pattern baldness); pharmaceutical preparations for the treatment of psychiatric diseases and disorders, namely, mood disorders, anxiety disorders, cognitive disorders, schizophrenia, and psychoses; pharmaceutical preparations for the treatment of damaged skin and tissue, namely, bee stings, sunburn, rashes, sores, corns, calluses and acne; pharmaceutical preparations for the treatment of inflammatory connective tissue diseases and injuries; pharmaceutical preparations for the treatment of malaria; pharmaceutical preparations for the treatment of tuberculosis; allergy medications; vaccines | ACTIVE | — |
Related trademarks
CopyMark links this record to cited §2(d) serials, the owner's other marks, Nice classes, similar mark names, and recently changed USPTO applications.
Prosecution history
| Date | Code | Event | What it means |
|---|---|---|---|
| May 30, 2025 | NREP | NEW REPRESENTATIVE AT IB RECEIVED | — |
| Jul 30, 2023 | ADCH | CHANGE OF NAME/ADDRESS REC'D FROM IB | — |
| Mar 12, 2022 | GPNX | NOTIFICATION PROCESSED BY IB | — |
| Feb 23, 2022 | FICS | FINAL DISPOSITION NOTICE SENT TO IB | — |
| Feb 22, 2022 | FIMP | FINAL DISPOSITION PROCESSED | — |
| Dec 9, 2021 | GPAR | GRANT OF PROTECTION CREATED, TO BE SENT TO IB | — |
| Nov 9, 2021 | R.PR | REGISTERED-PRINCIPAL REGISTER | Your trademark is registered on the Principal Register — the strongest form of federal trademark protection. You may use the ® symbol for the covered goods and services. Maintenance filings (Section 8 and renewals) are required to keep the registration alive. |
| Aug 24, 2021 | PUBO | PUBLISHED FOR OPPOSITION | Your mark was published in the USPTO Official Gazette for a 30-day opposition window. During that period, third parties who believe they would be harmed can file an opposition. If no opposition is filed, prosecution usually continues toward registration or a Notice of Allowance. |
| Aug 22, 2021 | GPNX | NOTIFICATION PROCESSED BY IB | — |
| Aug 4, 2021 | OPNS | NOTIFICATION OF POSSIBLE OPPOSITION SENT TO IB | — |
| Aug 4, 2021 | OP2R | NOTICE OF START OF OPPOSITION PERIOD CREATED, TO BE SENT TO IB | — |
| Aug 4, 2021 | NPUB | NOTICE OF PUBLICATION | — |
| Jul 20, 2021 | CNSA | APPROVED FOR PUB - PRINCIPAL REGISTER | — |
| Jul 19, 2021 | DOCK | ASSIGNED TO EXAMINER | — |
| Mar 19, 2021 | MAFR | APPLICATION FILING RECEIPT MAILED | — |
| Mar 15, 2021 | NWOS | NEW APPLICATION OFFICE SUPPLIED DATA ENTERED | — |
| Mar 12, 2021 | LIMI | LIMITATION FROM ORIGINAL APPLICATION ENTERED | — |
| Mar 11, 2021 | REPR | SN ASSIGNED FOR SECT 66A APPL FROM IB | — |